ZIOPHARM Oncology Inc (ZIOP):製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:ZIOPHARM Oncology Inc (ZIOP) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C3420
◆発行会社(調査会社):GlobalData
◆発行日:2018年8月
◆ページ数:55
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Ziopharm Oncology Inc (Ziopharm), formerly EasyWeb Inc, is a next-generation immune therapies provider. The company offers controlled IL-12 and t-cell therapy. Its next-generation immune therapie platform provides turning cold tumors hot by activating an immune response and non viral genetic modification of CART-T cells and TCRs. Ziopharm develops novel gene expression, control and cell technologies to provide cell-based therapies for the treatment of cancer and graft-versus-host-disease. The company provides cancer care services for solid tumors, brain cancer, pediatric cancer, and blood cancer. Its products and technologies are used in the treatment of hematologic malignancies, solid tumors and graft-versus-host-disease. Ziopharm is headquartered in Boston, Massachusetts, the US.

ZIOPHARM Oncology Inc (ZIOP) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
ZIOPHARM Oncology Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
ZIOPHARM Oncology Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
ZIOPHARM Oncology Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
ZIOPHARM Oncology Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
ZIOPHARM Oncology Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
ZIOPHARM Oncology Inc, Pharmaceuticals & Healthcare, Deal Details 11
Partnerships 11
ZIOPHARM, Intrexon Enter into Agreement with NCI 11
Intrexon Enters into Co-Development Agreement with Ziopharm Oncology 12
Ziopharm Expands Co-Development Agreement with Intrexon 13
Mesoblast Enters Into Co-Development Agreement With Intrexon And Ziopharm Oncology 14
Ziopharm Oncology Plans To Enter Into Co-Marketing Agreement For Palifosfamide 16
Licensing Agreements 17
Predictive Therapeutics Enters into Licensing Agreement with ZIOPHARM Oncology 17
Intrexon, Ziopharm Oncology Enter into Licensing Agreement with University of Texas MD Anderson Cancer Center 18
Equity Offering 20
ZIOPHARM Oncology Prices Private Placement of Shares for USD50 Million 20
Ziopharm Oncology Completes Exercise of Over-Allotment Option of Public Offering of Shares for USD100.6 Million 21
Ziopharm Oncology Completes Public Offering Of Shares For US$50 Million 22
ZIOPHARM Oncology Completes Public Offering Of Common Stock For US$50 Million 23
ZIOPHARM Oncology Inc – Key Competitors 25
ZIOPHARM Oncology Inc – Key Employees 26
ZIOPHARM Oncology Inc – Locations And Subsidiaries 27
Head Office 27
Other Locations & Subsidiaries 27
Recent Developments 28
Financial Announcements 28
Aug 08, 2018: Ziopharm Oncology reports second quarter 2018 financial results and provides corporate update 28
May 10, 2018: Ziopharm Oncology Reports First Quarter 2018 Financial Results and Provides Corporate Update 32
Mar 01, 2018: Ziopharm Oncology Reports Fourth Quarter and Full Year 2017 Financial Results and Provides Corporate Update 34
Nov 06, 2017: ZIOPHARM Oncology Reports Third Quarter 2017 Financial Results and Provides Update on Recent Activities 36
Jul 31, 2017: ZIOPHARM Oncology Reports Second Quarter 2017 Financial Results and Provides Update on Recent Activities 39
May 01, 2017: Ziopharm Oncology Reports First Quarter 2017 Financial Results and Provides Update on Recent Activities 42
Feb 16, 2017: ZIOPHARM Reports Fourth-Quarter 2016 Financial Results and Provides Update on Recent Activities 45
Corporate Communications 47
Aug 07, 2018: Ziopharm Oncology announces changes to its board of directors 47
Sep 28, 2017: ZIOPHARM Oncology Appoints David Mauney, M.D., as Executive Vice President and Chief Business Officer 48
Product News 49
Oct 23, 2017: A Virus, a Gene and a Pill Used to Harness the Immune System to Fight Brain Tumor in Children 49
09/01/2017: ZIOPHARM Oncology to Participate at Upcoming CAR-TCR Summit 50
Clinical Trials 51
Jun 18, 2018: Ziopharm Oncology Reports on Status of Investigational New Drug Application for Phase 1 Trial to Evaluate CD19-targeted CAR T Therapy 51
May 02, 2017: ZIOPHARM Oncology Announces FDA Acceptance of IND for CD33-Specific CAR-T Cell Therapy Targeting Relapsed/Refractory Acute Myeloid Leukemia 52
Jan 31, 2017: ZIOPHARM Utilizing Non-Viral Sleeping Beauty Platform to Rapidly Produce CAR-Expressing T cells Advancing “Point-of-Care” Approach 53
Other Significant Developments 54
Feb 06, 2018: Ziopharm Oncology Addresses Rumors and Stock Volatility, Affirms 2018 Guidance 54
Appendix 55
Methodology 55
About GlobalData 55
Contact Us 55
Disclaimer 55

List of Tables
ZIOPHARM Oncology Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
ZIOPHARM Oncology Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
ZIOPHARM Oncology Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
ZIOPHARM Oncology Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
ZIOPHARM Oncology Inc, Deals By Therapy Area, 2012 to YTD 2018 9
ZIOPHARM Oncology Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
ZIOPHARM, Intrexon Enter into Agreement with NCI 11
Intrexon Enters into Co-Development Agreement with Ziopharm Oncology 12
Ziopharm Expands Co-Development Agreement with Intrexon 13
Mesoblast Enters Into Co-Development Agreement With Intrexon And Ziopharm Oncology 14
Ziopharm Oncology Plans To Enter Into Co-Marketing Agreement For Palifosfamide 16
Predictive Therapeutics Enters into Licensing Agreement with ZIOPHARM Oncology 17
Intrexon, Ziopharm Oncology Enter into Licensing Agreement with University of Texas MD Anderson Cancer Center 18
ZIOPHARM Oncology Prices Private Placement of Shares for USD50 Million 20
Ziopharm Oncology Completes Exercise of Over-Allotment Option of Public Offering of Shares for USD100.6 Million 21
Ziopharm Oncology Completes Public Offering Of Shares For US$50 Million 22
ZIOPHARM Oncology Completes Public Offering Of Common Stock For US$50 Million 23
ZIOPHARM Oncology Inc, Key Competitors 25
ZIOPHARM Oncology Inc, Key Employees 26
ZIOPHARM Oncology Inc, Subsidiaries 27

List of Figures
ZIOPHARM Oncology Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
ZIOPHARM Oncology Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
ZIOPHARM Oncology Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
ZIOPHARM Oncology Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
ZIOPHARM Oncology Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
ZIOPHARM Oncology Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
ZIOPHARM Oncology Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
ZIOPHARM Oncology Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

★海外企業調査レポート[ZIOPHARM Oncology Inc (ZIOP):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • National Cheng Kung University:製薬・医療:M&Aディール及び事業提携情報
    Summary National Cheng Kung University (NCKU) is a research-led comprehensive university that offers educational and research services. The university’s services include graduate, undergraduate and postgraduate courses, research programs, master's programs, degree programs, doctoral courses, doctor' …
  • PT Central Proteina Prima Tbk (CPRO)
    PT Central Proteina Prima Tbk (CPRO) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company
  • Scynexis Inc (SCYX):企業の財務・戦略的SWOT分析
    Summary Scynexis Inc (Scynexis) is a pharmaceutical company that discovers, develops and commercializes novel anti-infective for various therapeutic needs. The company provides pipeline products such as SCY-078, is used for invasive fungal infections; SCY-635, is used for the treatment of Hepatitis …
  • Shionogi & Co., Ltd.:企業の戦略・SWOT・財務分析
    Shionogi & Co., Ltd. - Strategy, SWOT and Corporate Finance Report Summary Shionogi & Co., Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings …
  • Point Resources AS:石油・ガス:M&Aディール及び事業提携情報
    Summary Point Resources AS (Point Resources) ,is engaged in developing, exploring and production of petroleum products. It explores and produces crude oil, gas and natural gas liquids (NGLs) through Ringhorne, Balder and Jotun fields. Point Resources also offers seismic surveys and drilling services …
  • Reins International Inc.:企業の戦略・SWOT・財務分析
    Reins International Inc. - Strategy, SWOT and Corporate Finance Report Summary Reins International Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service o …
  • Pharmascience Inc:企業のM&A・事業提携・投資動向
    Pharmascience Inc - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Pharmascience Inc Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), div …
  • Canon Marketing Japan Inc (8060):企業の財務・戦略的SWOT分析
    Canon Marketing Japan Inc (8060) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and wea …
  • McWane, Inc.:企業の戦略・SWOT・財務分析
    McWane, Inc. - Strategy, SWOT and Corporate Finance Report Summary McWane, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate a …
  • Guangdong Zhongsheng Pharmaceutical Co Ltd (002317):製薬・医療:M&Aディール及び事業提携情報
    Summary Guangdong Zhongsheng Pharmaceutical Co Ltd (Guangdong Zhongsheng Pharma) is a pharmaceutical company that develops, manufactures and supplies Chinese patent medicines, medicinal herbs and chemical medicines. The company offers its products in the form of tablets, capsules, pills, injections, …
  • Statnett SF-エネルギー分野:企業M&A・提携分析
    Summary Statnett SF (Statnett) transmits and distributes high voltage electricity in Norway primarily generated from its hydro-electric power plants. It operates as a system operator in the Norwegian energy system. The company is a state enterprise, established under the Act relating to state-owned …
  • Innovation Pharmaceuticals Inc (IPIX)-医療機器分野:企業M&A・提携分析
    Summary Innovation Pharmaceuticals Inc (Innovation Pharmaceuticals), formerly Cellceutix Corp is a biopharmaceutical company that discovers and advances medical therapies with dermatology, oncology, anti-inflammatory and antibiotic applications. The company pipeline products include kevetrin for the …
  • K3 Business Technology Group plc (KBT):企業の財務・戦略的SWOT分析
    Summary K3 Business Technology Group plc (K3 BTG) is an information technology company that provides integrated business systems. The company offers products including axis fashion, fresh dynamics, MS dynamics AX, MS dynamics NAV, pebblestone fashion, sage, and syspro. Its services comprise CRM, ERP …
  • NewOcean Energy Holdings Ltd (342):企業の財務・戦略的SWOT分析
    NewOcean Energy Holdings Ltd (342) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and w …
  • Mohawk Industries, Inc.:企業の戦略・SWOT・財務分析
    Mohawk Industries, Inc. - Strategy, SWOT and Corporate Finance Report Summary Mohawk Industries, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service off …
  • Ceragon Networks Ltd (CRNT):企業の財務・戦略的SWOT分析
    Ceragon Networks Ltd (CRNT) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakness …
  • Schindler Holding Ltd.:戦略・SWOT・企業財務分析
    Schindler Holding Ltd. - Strategy, SWOT and Corporate Finance Report Summary Schindler Holding Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offer …
  • Nanion Technologies GmbH-医療機器分野:企業M&A・提携分析
    Summary Nanion Technologies GmbH (Nanion) is a biotechnology company that develops new innovations in the field of ion channel research and screening. The company offers products such as port-a-patch, patchliner, syncropatch 96, syncropatch 384pe, npc-chips, vesicle prep pro, ordering information, s …
  • TriMedx LLC:企業の戦略的SWOT分析
    TriMedx LLC - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services. …
  • VIA Technologies Inc (2388):企業の財務・戦略的SWOT分析
    VIA Technologies Inc (2388) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakness …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆